Obligate Roles for p16Ink4a and p19Arf-p53 in the Suppression of Murine Pancreatic Neoplasia

ABSTRACT Epithelial tumors of the pancreas exhibit a wide spectrum of histologies with varying propensities for metastasis and tissue invasion. The histogenic relationship among these tumor types is not well established; moreover, the specific role of genetic lesions in the progression of these malignancies is largely undefined. Transgenic mice with ectopic expression of transforming growth factor alpha (TGF-α) in the pancreatic acinar cells develop tubular metaplasia, a potential premalignant lesion of the pancreatic ductal epithelium. To evaluate the cooperative interactions between TGF-α and signature mutations in pancreatic tumor genesis and progression, TGFα transgenic mice were crossed onto Ink4a/Arf and/or p53 mutant backgrounds. These compound mutant mice developed a novel pancreatic neoplasm, serous cystadenoma (SCA), presenting as large epithelial tumors bearing conspicuous gross and histological resemblances to their human counterpart. TGFα animals heterozygous for both the Ink4a/Arf and the p53 mutation showed a dramatically increased incidence of SCA, indicating synergistic interaction of these alleles. Inactivation of p16 Ink4a by loss of heterozygosity, intragenic mutation, or promoter hypermethylation was a common feature in these SCAs, and correspondingly, none of the tumors expressed wild-type p16Ink4a. All tumors sustained loss of p53 or Arf, generally in a mutually exclusive fashion. The tumor incidence data and molecular profiles establish a pathogenic role for the dual inactivation of p16Ink4a and p19Arf-p53 in the development of SCA in mice, demonstrating that p16Ink4a is a murine tumor suppressor. This genetically defined model provides insights into the molecular pathogenesis of SCA and serves as a platform for dissection of cell-specific programs of epithelial tumor suppression.

[1]  D. Carrasco,et al.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.

[2]  A. Szalay,et al.  The p14ARF Tumor Suppressor Protein Facilitates Nucleolar Sequestration of Hypoxia-inducible Factor-1α (HIF-1α) and Inhibits HIF-1-mediated Transcription* , 2001, The Journal of Biological Chemistry.

[3]  T. Shuin,et al.  Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth , 2001, Oncogene.

[4]  L. Chin,et al.  Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.

[5]  R. Klausner,et al.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Tlsty,et al.  Know thy neighbor: stromal cells can contribute oncogenic signals. , 2001, Current opinion in genetics & development.

[7]  M. Ivan,et al.  The von Hippel-Lindau tumor suppressor protein. , 2001, Current opinion in genetics & development.

[8]  T. Mattfeldt,et al.  A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. , 2001, Genes & development.

[9]  R. DePinho,et al.  Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility , 2001, Molecular and Cellular Biology.

[10]  A. Scarpa,et al.  Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. , 2001, The American journal of pathology.

[11]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[12]  S. Libutti,et al.  Histopathology and molecular genetics of multiple cysts and microcystic (serous) adenomas of the pancreas in von Hippel-Lindau patients. , 2000, The American journal of pathology.

[13]  J. Barrett,et al.  Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines. , 2000, Carcinogenesis.

[14]  F. Alt,et al.  Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. , 2000, Genes & development.

[15]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[16]  C. Compton Serous cystic tumors of the pancreas. , 2000, Seminars in diagnostic pathology.

[17]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[18]  M. Washington,et al.  Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. , 1999, Gastroenterology.

[19]  N. Sarvetnick,et al.  PDX-1 and Msx-2 expression in the regenerating and developing pancreas. , 1999, The Journal of endocrinology.

[20]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[21]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[22]  M. You,et al.  Cdkn2a encodes functional variation of p16INK4a but not p14ARF, which confers selection in mouse lung tumorigenesis , 1999, Molecular carcinogenesis.

[23]  R. Fåhraeus,et al.  The p16INK4a tumour suppressor protein inhibits αvβ3 integrin‐mediated cell spreading on vitronectin by blocking PKC‐dependent localization of αvβ3 to focal contacts , 1999 .

[24]  S. Bonner-Weir,et al.  The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. , 1999, Diabetes.

[25]  R. DePinho,et al.  The INK4A/ARF locus and its two gene products. , 1999, Current opinion in genetics & development.

[26]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[27]  F. Oesch,et al.  p16INK4 mediates contact-inhibition of growth , 1999, Oncogene.

[28]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[29]  R. DePinho,et al.  p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[31]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[32]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[33]  S. Lowe,et al.  E1A signaling to p53 involves the p19(ARF) tumor suppressor. , 1998, Genes & development.

[34]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Edlund,et al.  beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. , 1998, Genes & development.

[36]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[37]  E. Ramsay,et al.  Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  V. Sukhatme,et al.  Transforming Growth Factor α Is a Target for the Von Hippel-Lindau Tumor Suppressor , 1998 .

[39]  C. D. Edwards,et al.  p16INK4A Participates in a G1 Arrest Checkpoint in Response to DNA Damage , 1998, Molecular and Cellular Biology.

[40]  V. Sukhatme,et al.  Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. , 1998, Cancer research.

[41]  S. Lowe,et al.  E1A signaling to p53 involves the p19 tumor suppressor , 1998 .

[42]  S. Lowe,et al.  A signaling to p 53 involves the p 19 ARF tumor suppressor , 1998 .

[43]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[44]  B. Amati,et al.  Cyclin E and c‐Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins , 1997, The EMBO journal.

[45]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[47]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[48]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[49]  J. Slack Developmental biology of the pancreas. , 1995, Development.

[50]  T. Wang,et al.  Transforming growth factor alpha disrupts the normal program of cellular differentiation in the gastric mucosa of transgenic mice. , 1995, Development.

[51]  H. Edlund,et al.  Insulin-promoter-factor 1 is required for pancreas development in mice , 1994, Nature.

[52]  R. DePinho,et al.  p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens , 1994, Nature.

[53]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[54]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[55]  G. Merlino,et al.  Cytological changes in the pancreas of transgenic mice overexpressing transforming growth factor alpha. , 1992, Gastroenterology.

[56]  R. Sharp,et al.  Hypertrophic gastropathy resembling Ménétrier's disease in transgenic mice overexpressing transforming growth factor alpha in the stomach. , 1992, The Journal of clinical investigation.

[57]  I. Ihse,et al.  The importance of the centroacinar region in cerulein-induced mouse pancreatic growth. , 1992, Scandinavian journal of gastroenterology.

[58]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[59]  C. Compton,et al.  Cystic tumors of the pancreas : new clinical, radiologic, and pathologic observations in 67 patients. Discussion , 1990 .

[60]  G. Merlino,et al.  TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas , 1990, Cell.

[61]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[62]  P. Pour,et al.  Ductal metaplasia of human exocrine pancreas and its association with carcinoma. , 1985, Cancer research.

[63]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.